日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma

一种提高莫苏妥珠单抗治疗复发或难治性滤泡性淋巴瘤获益风险比的新型递增剂量方案

Li, Chi-Chung; Bender, Brendan; Wilkins, Justin; Li, Feifei; Turner, David C; Wang, Bei; Deng, Rong; Vadhavkar, Shweta; Li, Zao; Kwan, Antonia; Huang, Huang; Peng, Kun; Penuel, Elicia; Huw, Ling-Yuh; Chanu, Pascal; Li, Chunze; Yin, Shen; Wei, Michael C

Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma.

莫苏妥珠单抗在中国复发或难治性滤泡性淋巴瘤患者中的药代动力学和药效学的种族敏感性评估

Li Junyi, Liao Michael Z, Wilkins Justin, Penuel Elicia, Wang Bei, Vadhavkar Shweta, Peng Kun, Cao Junning, Li Zhiming, Zhang Ye, Li Wenjin, Li Donghang, Zhou Mingzhu, Wei Michael C, Kwan Antonia, Zhao Rong, Li Chunze, Li Chi-Chung, Turner David C

Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma

莫苏妥珠单抗在复发/难治性B细胞非霍奇金淋巴瘤中的群体药代动力学和CD20结合动力学

Bender, Brendan; Li, Chi-Chung; Marchand, Mathilde; Turner, David C; Li, Feifei; Vadhavkar, Shweta; Wang, Bei; Deng, Rong; Lu, James; Jin, Jin; Li, Chunze; Yin, Shen; Wei, Michael; Chanu, Pascal

Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial

维奈托克+奥妥珠单抗治疗慢性淋巴细胞白血病的药代动力学和暴露-反应分析:1b期研究和3期CLL14试验

Samineni, Divya; Gibiansky, Leonid; Wang, Bei; Vadhavkar, Shweta; Rajwanshi, Richa; Tandon, Maneesh; Sinha, Arijit; Al-Sawaf, Othman; Fischer, Kirsten; Hallek, Michael; Salem, Ahmed Hamed; Li, Chunze; Miles, Dale

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)

阿特珠单抗免疫原性评价:临床药理学(第一部分)

Wu, Benjamin; Sternheim, Nitzan; Agarwal, Priya; Suchomel, Julia; Vadhavkar, Shweta; Bruno, Rene; Ballinger, Marcus; Bernaards, Coen A; Chan, Phyllis; Ruppel, Jane; Jin, Jin; Girish, Sandhya; Joshi, Amita; Quarmby, Valerie

Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region

阿特珠单抗和贝伐珠单抗治疗不可切除肝细胞癌患者:基于肝功能损害状态和地理区域的药代动力学和安全性评估

Shemesh, Colby S; Chan, Phyllis; Shao, Hui; Xu, Derek-Zhen; Combs, Daniel; Vadhavkar, Shweta; Bruno, René; Wu, Benjamin

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework

预测接受阿特珠单抗治疗的实体瘤患者的总生存期:肿瘤生长抑制-总生存期建模框架

Chan, Phyllis; Marchand, Mathilde; Yoshida, Kenta; Vadhavkar, Shweta; Wang, Nina; Lin, Alyse; Wu, Benjamin; Ballinger, Marcus; Sternheim, Nitzan; Jin, Jin Y; Bruno, René

Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires

基于生物标志物、肺功能测定和日记/问卷的哮喘急性发作预测新方法:对哮喘患者急性发作进行重复时间事件分析

Svensson, Robin J; Ribbing, Jakob; Kotani, Naoki; Dolton, Michael; Vadhavkar, Shweta; Cheung, Dorothy; Staton, Tracy; Choy, David F; Putnam, Wendy; Jin, Jin; Budha, Nageshwar; Karlsson, Mats O; Quartino, Angelica; Zhu, Rui

Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden

在肿瘤突变负荷高的患者中,对阿特珠单抗进行泛癌人群药代动力学、暴露-安全性和-疗效分析

Shemesh, Colby S; Chan, Phyllis; Legrand, Fatema A; Shames, David S; Das Thakur, Meghna; Shi, Jane; Bailey, Lorna; Vadhavkar, Shweta; He, Xian; Zhang, Wei; Bruno, René